175 related articles for article (PubMed ID: 20714945)
1. Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer.
Hu CY; Delclos GL; Chan W; Du XL
Med Oncol; 2011 Dec; 28(4):1062-74. PubMed ID: 20714945
[TBL] [Abstract][Full Text] [Related]
2. Completion of therapy by Medicare patients with stage III colon cancer.
Dobie SA; Baldwin LM; Dominitz JA; Matthews B; Billingsley K; Barlow W
J Natl Cancer Inst; 2006 May; 98(9):610-9. PubMed ID: 16670386
[TBL] [Abstract][Full Text] [Related]
3. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.
Neugut AI; Matasar M; Wang X; McBride R; Jacobson JS; Tsai WY; Grann VR; Hershman DL
J Clin Oncol; 2006 May; 24(15):2368-75. PubMed ID: 16618946
[TBL] [Abstract][Full Text] [Related]
4. Age and adjuvant chemotherapy use after surgery for stage III colon cancer.
Schrag D; Cramer LD; Bach PB; Begg CB
J Natl Cancer Inst; 2001 Jun; 93(11):850-7. PubMed ID: 11390534
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer.
Iwashyna TJ; Lamont EB
J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596
[TBL] [Abstract][Full Text] [Related]
6. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer.
Hu CY; Chan W; Delclos GP; Du XL
Am J Clin Oncol; 2012 Jun; 35(3):228-36. PubMed ID: 21383605
[TBL] [Abstract][Full Text] [Related]
8. The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients.
Hsieh MC; Thompson T; Wu XC; Styles T; O'Flarity MB; Morris CR; Chen VW
Cancer Med; 2016 May; 5(5):871-80. PubMed ID: 26773804
[TBL] [Abstract][Full Text] [Related]
9. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis.
Green SL; Dawe DE; Nugent Z; Cheung WY; Czaykowski PM
J Geriatr Oncol; 2019 Jan; 10(1):132-137. PubMed ID: 30104156
[TBL] [Abstract][Full Text] [Related]
10. Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Petito LC; García-Albéniz X; Logan RW; Howlader N; Mariotto AB; Dahabreh IJ; Hernán MA
JAMA Netw Open; 2020 Mar; 3(3):e200452. PubMed ID: 32134464
[TBL] [Abstract][Full Text] [Related]
11. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.
Hershman D; Hall MJ; Wang X; Jacobson JS; McBride R; Grann VR; Neugut AI
Cancer; 2006 Dec; 107(11):2581-8. PubMed ID: 17078055
[TBL] [Abstract][Full Text] [Related]
12. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Population-Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992-2009.
Du XL; Zhang Y; Parikh RC; Lairson DR; Cai Y
J Am Geriatr Soc; 2015 Aug; 63(8):1570-82. PubMed ID: 26200214
[TBL] [Abstract][Full Text] [Related]
14. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.
Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB
J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.
Jessup JM; Stewart A; Greene FL; Minsky BD
JAMA; 2005 Dec; 294(21):2703-11. PubMed ID: 16333005
[TBL] [Abstract][Full Text] [Related]
17. Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer.
van der Geest LG; Portielje JE; Wouters MW; Weijl NI; Tanis BC; Tollenaar RA; Struikmans H; Nortier JW;
Colorectal Dis; 2013; 15(10):e582-91. PubMed ID: 23679338
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.
Jiao X; Hay JW; Sadeghi S; Barzi A
Am J Clin Oncol; 2020 Jun; 43(6):428-434. PubMed ID: 32187027
[TBL] [Abstract][Full Text] [Related]
19. Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.
Hsieh MC; Chiu YW; Velasco C; Wu XC; O'Flarity MB; Chen VW
J Registry Manag; 2013; 40(4):180-7. PubMed ID: 24625772
[TBL] [Abstract][Full Text] [Related]
20. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.
Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI
Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
